INIS
kidneys
100%
diseases
100%
proteins
100%
biological markers
83%
high-performance liquid chromatography
50%
raman effect
50%
mass spectrometry
50%
spectroscopy
50%
validation
50%
surfaces
50%
filtration
25%
urine
18%
patients
18%
populations
16%
assessments
16%
abundance
15%
control
13%
research programs
8%
Keyphrases
Protein Biomarkers
75%
Urinary Protein
68%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
50%
Glomerular Kidney Disease
50%
Diabetic Kidney Disease
50%
Surface-enhanced Raman Scattering Spectroscopy
50%
Proteomic Study
41%
Urine Proteome
39%
Kidney Function
25%
Chronic Kidney Disease
25%
Estimated Glomerular Filtration Rate Decline
25%
Chronic Kidney Disease Patients
18%
Surface-enhanced Raman Scattering
16%
Fibrillin-1 (FBN1)
15%
Kidney
12%
Kidney Disease Progression
12%
Collaborative Research
8%
A1BG
6%
Associated Complications
6%
Chronic Kidney Disease Stage
6%
Urine Samples
6%
Specific Difference
6%
Proteomic Analysis
6%
Protein Abundance
6%
Patient-controlled
6%
KNG1
6%
CD59
6%
Modified Proteins
6%
Healthy Controls
6%
Abundance Index
6%
Total Protein
6%
Negative Association
6%
Potential Impact
6%
Disease Severity
6%
Proteinuria
6%
Cluster of Differentiation 44 (CD44)
6%
Peptide Quantification
5%
Diseases Therapeutic
5%
Biochemistry, Genetics and Molecular Biology
Protein Urine Level
68%
Proteomics
41%
High Performance Liquid Chromatography-Mass Spectrometry
25%
Surface-Enhanced Raman Spectroscopy
25%
Kidney Function
25%
High-Performance Liquid Chromatography
25%
Liquid Chromatography-Mass Spectrometry
25%
FBN1
18%
Proteomics
16%
CD59
6%
CD44
6%
Urine Sampling
6%
Proteome
6%